Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (USFDA) to market a generic version of Ibrutinib, a drug widely used in the treatment of several blood cancers including mantle cell lymphoma and chronic lymphocytic leukemia. This regulatory clearance marks a significant addition to the company’s growing oncology portfolio and underscores its strategy to enhance access to high-value therapies in international markets.